PFM
RPRX icon

Privium Fund Management’s Royalty Pharma RPRX Stock Holding History

Privium Fund Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-243,322
Closed -$9.48M – 282
2022
Q1 		$9.48M Buy
243,322
+333
+0.1% +$13.1K 2.1% 12
2021
Q4 		$9.74M Buy
+242,989
New +$9.44M 1.93% 15

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Privium Fund Management's RPRX Position: Q2 2022 in Review

Privium Fund Management sold out of Royalty Pharma (RPRX) in Q2 2022, closing a stake of 243,322 shares — an estimated $9.48M sold.

Privium Fund Management first reported a position in RPRX in Q4 2021 and held it in 2 quarters. The position peaked at $9.74M in Q4 2021. 283 funds tracked by Wall St. Rank hold RPRX as of Q2 2022.

  • Privium Fund Management reported no remaining Royalty Pharma position as of Q2 2022 after selling out during the quarter.
  • Privium Fund Management sold 243,322 Royalty Pharma shares in Q2 2022, an estimated $9.48M.
  • Privium Fund Management first reported a position in Royalty Pharma in Q4 2021 and held it in 2 quarters.
  • Privium Fund Management's Royalty Pharma position peaked at $9.74M in Q4 2021.
  • 283 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2022.

Based on Privium Fund Management's 13F filing for Q2 2022, filed 28 Jul 2022.